Lesson plan

ESHAP

ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin lymphoma. In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R. R-ESHAP consists of: # Rituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes # Etoposide, an epipodophyllotoxin topoisomerase inhibitor # Solu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse lymphocytes # High-dose Ara-C - cytarabine # Platinol - Cisplatin, a platinum-based antineoplastic agent, also an alkylating antineoplastic agent.

Back to article

Article summary

ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin lymphoma. In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R. R-ESHAP consists of: # Rituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes # Etoposide, an epipodophyllotoxin topoisomerase inhibitor # Solu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse lymphocytes # High-dose Ara-C - cytarabine # Platinol - Cisplatin, a platinum-based antineoplastic agent, also an alkylating antineoplastic agent.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.